KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Free Cash Flow: 2009-2025

Historic Free Cash Flow for Novavax (NVAX) over the last 17 years, with Sep 2025 value amounting to $105.8 million.

  • Novavax's Free Cash Flow rose 172.36% to $105.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$383.8 million, marking a year-over-year decrease of 246.26%. This contributed to the annual value of -$100.4 million for FY2024, which is 86.93% up from last year.
  • According to the latest figures from Q3 2025, Novavax's Free Cash Flow is $105.8 million, which was up 182.81% from -$127.7 million recorded in Q2 2025.
  • In the past 5 years, Novavax's Free Cash Flow ranged from a high of $649.3 million in Q1 2021 and a low of -$355.8 million during Q4 2021.
  • For the 3-year period, Novavax's Free Cash Flow averaged around -$97.9 million, with its median value being -$146.2 million (2024).
  • Over the last 5 years, Novavax's Free Cash Flow had its largest YoY gain of 2,894.51% in 2021, and its largest YoY loss of 913.81% in 2021.
  • Over the past 5 years, Novavax's Free Cash Flow (Quarterly) stood at -$355.8 million in 2021, then skyrocketed by 60.41% to -$140.8 million in 2022, then tumbled by 31.80% to -$185.6 million in 2023, then rose by 5.65% to -$175.1 million in 2024, then soared by 172.36% to $105.8 million in 2025.
  • Its Free Cash Flow was $105.8 million in Q3 2025, compared to -$127.7 million in Q2 2025 and -$186.7 million in Q1 2025.